Lingua originale | Inglese |
---|---|
pagine (da-a) | e770-e772 |
Rivista | Journal of the European Academy of Dermatology and Venereology |
Volume | 34 |
Numero di pubblicazione | 12 |
DOI | |
Stato di pubblicazione | Pubblicato - dic 2020 |
OSS delle Nazioni Unite
Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile
Accesso al documento
Altri file e collegamenti
Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of the European Academy of Dermatology and Venereology, Vol. 34, N. 12, 12.2020, pag. e770-e772.
Risultato della ricerca: Contributo su rivista › Lettera › peer review
TY - JOUR
T1 - Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy
AU - PSO-BIO-COVID study group
AU - Talamonti, M.
AU - Galluzzo, M.
AU - Chiricozzi, A.
AU - Quaglino, P.
AU - Fabbrocini, G.
AU - Gisondi, P.
AU - Marzano, A. V.
AU - Potenza, C.
AU - Conti, A.
AU - Parodi, A.
AU - Belloni Fortina, A.
AU - Bardazzi, F.
AU - Argenziano, G.
AU - Rongioletti, F.
AU - Stingeni, L.
AU - Micali, G.
AU - Loconsole, F.
AU - Venturini, M.
AU - Bongiorno, M. R.
AU - Feliciani, C.
AU - Rubegni, P.
AU - Amerio, P.
AU - Fargnoli, M. C.
AU - Pigatto, P.
AU - Savoia, P.
AU - Nisticò, S. P.
AU - Giustini, S.
AU - Carugno, A.
AU - Cannavò, S. P.
AU - Rech, G.
AU - Prignano, F.
AU - Offidani, A.
AU - Lombardo, M.
AU - Zalaudek, I.
AU - Bianchi, L.
AU - Peris, K.
AU - Balestri, R.
AU - Bernardini, N.
AU - Botti, E.
AU - Burlando, M.
AU - Caldarola, G.
AU - Cattaneo, A.
AU - Dapavo, P.
AU - Dastoli, S.
AU - De Simone, C.
AU - Di Nuzzo, S.
AU - Diotallevi, F.
AU - Fierro, M. T.
AU - Fidanza, R.
AU - Foti, C.
N1 - Funding Information: L. Bianchi reports personal fees from speaker and as consultant for AbbVie, Novartis, Janssen‐Cilag, Pfizer, UCB and Leo Pharma, outside the submitted work. SP Cannavò has served as speaker or board member for AbbVie, Celgene, Eli Lilly, Leo Pharma, Janssen, Novartis and Sanofi Genzyme. A. Chiricozzi served as advisory board member and consultant and has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Fresenius Kabi, Leo Pharma, Lilly, Janssen, Novartis, Sanofi Genzyme and UCB Pharma. A. Conti served as advisory board member and consultant, and has received fees and speaker’s honoraria or has participated in clinical trials for AbbVie, Leo Pharma, Eli Lilly, Novartis, UCB Pharma, Pfizer, Sandoz, Celgene, Biogen and Janssen‐Cilag. M.C. Fargnoli has served on advisory boards, received honoraria for lectures and research grants from Almirall, AbbVie, Galderma, Leo Pharma, Mylan, Medac Pharma, Celgene, Pierre Fabre, UCB, Eli Lilly, Pfizer, Janssen, Novartis, Sanofi Genzyme, Roche, Sun Pharma and MSD. P. Gisondi has been a consultant and/or speaker for AbbVie, Almirall, Celgene, Janssen, Leo pharma, Eli Lilly, Novartis, Pfizer, Sandoz and UCB. K. Peris reports personal fees for advisory board meeting from Almirall, AbbVie, Biogen, Janssen, Eli Lilly, Celgene, Galderma, Leo Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz and Sun Pharma outside the conduct of the work. I. Zalaudek has been a consultant and/or speaker for Novartis, Celgene and Amgen.
PY - 2020/12
Y1 - 2020/12
UR - http://www.scopus.com/inward/record.url?scp=85089190434&partnerID=8YFLogxK
U2 - 10.1111/jdv.16841
DO - 10.1111/jdv.16841
M3 - Letter
SN - 0926-9959
VL - 34
SP - e770-e772
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
IS - 12
ER -